lncRNA MCF2L-AS1/miR-105/ IL-1β Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance

Cai, Mao; Hu, Wanle; Huang, Chun-Chieh; Zhou, Chong‐Jun; Li, Jiante; Chen, Yanyu; Yu, Yan

doi:10.2147/cmar.s313905

Cited by 6 publications

(3 citation statements)

References 27 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MCF2L-AS1 is a lncRNA that was recently identified and found to be dysregulated in multiple human cancer types in which it regulates progression-related disease processes [ 11 ]. Cai et al showed MCF2L-AS1/miR-105/ IL-1β Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance [ 45 ]. Zhang et al showed MCF2L-AS1 aggravates proliferation, invasion, and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXM1 signaling axis [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most prevalent gynecologic malignant tumors with a poor prognosis and the second leading cause of cancer-related deaths in women worldwide. In recent years, it has been shown that long non-coding RNA (lncRNA) plays an important role in the development of breast cancer (BC). An antisense lncRNA from the MCF2 cell line (MCF2L-AS1) has been discovered recently and has been shown to function in a variety of malignancies. However, its function as a regulator of BC development has yet to be determined. Herein, the bioinformatics study analysis showed that MCF2L-AS1 was frequently highly expressed in BC tumors, and this overexpression was associated with worse patient outcomes. BC cells’ proliferation, migration, and invasion are inhibited when MCF2L-AS1 is silenced, whereas the inverse is evident when MCF2L-AS1 is overexpressed. It was also observed that MCF2L-AS1 knockdown decreased carcinogenesis in xenograft tumor models. Furthermore, we discovered that MCF2L-AS1 could bind to and improve the transcription activity of the yes-associated protein (YAP). However, following YAP knockdown, this lncRNA’s ability to drive BC malignancy was considerably reduced. In conclusion, MCF2L-AS1 may represent a potential predictive biomarker in BC patients, as well as a key regulator of BC cell proliferation. It works through positive feedback processes involving direct YAP binding and subsequent modulation of intracellular gene expression. Our findings add to our understanding of MCF2L-AS1 regulation and its potential as a therapeutic target in patients with this fatal cancer type.

show abstract

Section: Discussionmentioning

confidence: 99%

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…LncRNA MCF2-AS1 shows upregulation in CRC and reduces response of tumor cells to chemotherapy. LncRNA MCF2-AS1 reduces miR-105 expression to upregulate IL-1β in triggering OXA resistance in CRC cells [ 145 ]. LncRNA BLACAT1 is another oncogenic factor [ 146 ] that can sponge miRNAs [ 147 ] and it regulates tumor hallmarks such as growth, invasion and glycolysis [ 148 ].…”

Section: Non-coding Rnas and Oxaliplatin Chemotherapymentioning

confidence: 99%

Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer

Hashemi,

Esbati,

Rashidi

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

“…Cai et al. reported that knockdown of MCF2L-AS1 can alleviate the chemoresistance of CRC/OXA cells ( 161 ). Zhou et al.’s research reported that MIR155HG promotes CRC progression and enhances CRC cell resistance to oxaliplatin by regulating the miR-650/ANXA2 axis and through M2 macrophage polarization ( 163 ).…”

Section: Lncrnas Regulate Drug Resistancementioning

confidence: 99%

The functions and mechanisms of long non-coding RNA in colorectal cancer

Lin,

Zhao,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

CRC poses a significant challenge in the global health domain, with a high number of deaths attributed to this disease annually. If CRC is detected only in its advanced stages, the difficulty of treatment increases significantly. Therefore, biomarkers for the early detection of CRC play a crucial role in improving patient outcomes and increasing survival rates. The development of a reliable biomarker for early detection of CRC is particularly important for timely diagnosis and treatment. However, current methods for CRC detection, such as endoscopic examination, blood, and stool tests, have certain limitations and often only detect cases in the late stages. To overcome these constraints, researchers have turned their attention to molecular biomarkers, which are considered a promising approach to improving CRC detection. Non-invasive methods using biomarkers such as mRNA, circulating cell-free DNA, microRNA, LncRNA, and proteins can provide more reliable diagnostic information. These biomarkers can be found in blood, tissue, stool, and volatile organic compounds. Identifying molecular biomarkers with high sensitivity and specificity for the early and safe, economic, and easily measurable detection of CRC remains a significant challenge for researchers.

show abstract

lncRNA MCF2L-AS1/miR-105/ IL-1β Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance

Cited by 6 publications

References 27 publications

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis

Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer

The functions and mechanisms of long non-coding RNA in colorectal cancer

Contact Info

Product

Resources

About